During the COVID-19 pandemic, the Ludwig Institute for Cancer Research, Oxford Branch is taking measures to prevent the spread of the disease.
Departments are instructed by the University’s Registrar to continue to work from home where possible, and manage the return to on site working, based on the University guidelines for risk assessments and work prioritisation.
This is to restrict contact between individuals as far as possible. The University remains open and operating as far as possible with the following restrictions:
- No public access to the University
- On-site activity permitted where it cannot be undertaken remotely, driven by safety, capacity and other factors such as schools reopening/other changes in government guidelines
- Teaching and assessment are undertaken remotely where possible and, depending on government guidelines, gatherings of staff and students only permitted where essential for teaching and assessment to take place
Find out more: www.ox.ac.uk/covid-health
Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities.
Ludwig Oxford Branch researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Our research groups are interested in the signalling pathways that influence cancer initiation and progression, with a focus on infection, inflammation and cancer epigenetics. We aim to advance cancer prevention, early diagnosis and effective treatment. Find out more about the Ludwig Oxford research groups.
Sánchez-Del-Campo L. et al, (2021), J Exp Clin Cancer Res, 40
Munshaw S. et al, (2021), J Clin Invest
Ghosh A. et al, (2021), Cancers, 13, 1 - 15